Prostate Cancer Screening

Tenke, Péter; Horti, J.; Bálint, Péter; Kovács, Béla

doi:10.1007/978-3-540-40901-4_5

Cited by 24 publications

(14 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Existing approaches for diagnosing prostate cancer features digital rectal examination screening and serum prostatespecific antigen (PSA) determination (3). However, because of their limited sensitivity and specificity, these methods cannot reliably identify early-stage prostate cancer (4). The clinicopathologic features predictive of prostate cancer consist of Gleason score, tumor-node-metastasis (TNM) stage, surgical margin status, preoperative serum PSA levels, and GPSM (Gleason score, preoperative PSA, seminal vesicle involvement, and marginal status) score.…”

Section: Introductionmentioning

confidence: 99%

Global Methylation Profiling for Risk Prediction of Prostate Cancer

Mahapatra

Klee

Young

et al. 2012

Clinical Cancer Research

122

104

View full text Add to dashboard Cite

Purpose: The aim of this study was to investigate the promoter hypermethylation as diagnostic markers to detect malignant prostate cells and as prognostic markers to predict the clinical recurrence of prostate cancer.Experimental Design: DNA was isolated from prostate cancer and normal adjacent tissues. After bisulfite conversion, methylation of 14,495 genes was evaluated using the Methylation27 microarrays in 238 prostate tissues. We analyzed methylation profiles in four different groups: (i) tumor (n ¼ 198) versus matched normal tissues (n ¼ 40), (ii) recurrence (n ¼ 123) versus nonrecurrence (n ¼ 75), (iii) clinical recurrence (n ¼ 80) versus biochemical recurrence (n ¼ 43), and (iv) systemic recurrence (n ¼ 36) versus local recurrence (n ¼ 44). Group 1, 2, 3, and 4 genes signifying biomarkers for diagnosis, prediction of recurrence, clinical recurrence, and systemic progression were determined. Univariate and multivariate analyses were conducted to predict risk of recurrence. We validated the methylation of genes in 20 independent tissues representing each group by pyrosequencing.Results: Microarray analysis revealed significant methylation of genes in four different groups of prostate cancer tissues. The sensitivity and specificity of methylation for 25 genes from 1, 2, and 4 groups and 7 from group 3 were shown. Validation of genes by pyrosequencing from group 1 (GSTP1, HIF3A, HAAO, and RARb), group 2 (CRIP1, FLNC, RASGRF2, RUNX3, and HS3ST2), group 3 (PHLDA3, RASGRF2, and TNFRSF10D), and group 4 (BCL11B, POU3F3, and RASGRF2) confirmed the microarray results.Conclusions: Our study provides a global assessment of DNA methylation in prostate cancer and identifies the significance of genes as diagnostic and progression biomarkers of prostate cancer. Clin Cancer Res; 18(10); 2882-95. Ó2012 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Global Methylation Profiling for Risk Prediction of Prostate Cancer

Mahapatra

Klee

Young

et al. 2012

Clinical Cancer Research

122

104

View full text Add to dashboard Cite

show abstract

“…Prostate cancer rarely causes symptoms early in the course of the disease because the majority of adenocarcinomas arise in the periphery of the gland distant from the urethra. 5 The presence of periphery of the gland distant from the urethra. The presence of symptoms as a result of prostate cancer suggests locally advanced or monastic disease.…”

Section: Introductionmentioning

confidence: 99%

Is serum glutathione level in combination with serum PSA useful for early detection of prostatic carcinoma? A local study of Iraq

Mohammad¹

2018

Int Surg J

View full text Add to dashboard Cite

Background: Prostate cancer is the most common cancer and the second leading cause of cancer-related death among men of western countries. The aim of this study is to develop non-invasive diagnostic tools for the early detection of prostate cancer (PCa) through detection of low level of Serum reduced Glutathione (GSH).Methods: Serum samples from men being evaluated for PCa were analyzed for reduced Glutathione (GSH) level. The results were compared with the prostate needle biopsy findings and (PSA) level combined with Digital Rectal Examination (DRE). Samples were obtained from 59 cases including 18 controls.Results: The maximum sensitivity of the test was observed in the first category of confirmed cases with 93.33% turs positive detected with low GSH. Among those highly suspected Ca prostate there was 87.5% true positive test and 12.5% false negative results. Among those in grey zone where PSA between is 4 and 10, and DRE is suggestive, the proportion of true positive was 50%.Conclusions: These results demonstrate that serum reduced Glutathione (GSH) level is helpful in patient with definite carcinoma. This test could be useful in augmenting current PCa diagnostic procedures. For example, the examination test for reduced Glutathione (GSH) level with an elevated prostate- specific antigen level might be used in predicting which patients will have negative biopsies and may be used as treatment modality for PCa.

show abstract

“…Though the PSA test is the first step towards a cancer diagnosis, it lacks specificity because elevated PSA levels may signal conditions other than cancer like BPH and prostatitis. Thus, PSA can no longer be considered as a classical tumor marker whose levels are directly correlated with increasing stage of the disease [12], [13], [14].…”

Section: Introductionmentioning

confidence: 99%

Comparison Between Circulating Immune Complexes and Prostate Specific Antigen to Assess the Pathogenesis of Prostate Cancer

Nerurkar¹

2017

JCTR

View full text Add to dashboard Cite

Prostrate cancer is a common cancer in males with increasing rate of incidence these days. Two known markers prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) have been used for diagnosis and in the clinical management of prostate cancer patients. PAP and PSA tests are not specific and hence not reliable. Therefore, certain immunological tests need to be developed to aid the clinicians in early detection, metastasis and recurrence and also to follow clinical course of the disease and/or its response to therapy. The present study shows that the circulating immune complexes (CICs) may be associated with the pathogenesis of prostate cancer and their progression. CICs were investigated in 50 prostate cancer patients having different grades of the disease and 45 benign prostate hyperplasia patients (BPH). Estimation of CICs was done using 3.75% Polyethylene glycol 6000 (PEG) serum precipitation. The results obtained were compared with normal healthy individuals. 83.33% and 91.66% positivity was observed in Grade I and Grade II prostate carcinomas respectively, whereas 100% positivity was observed in Grade III and Grade IV prostate carcinoma. BPH patients showed 60% positivity. Strong positive correlation (r=0.5748) between Prostate specific antigen (PSA) and CIC was observed in prostate cancer patients. Present investigation shows CICs may be associated with the pathogenesis of prostate cancers. The further qualitative analysis of CICs may help us to formulate specific immunological tests for early detection, management and monitoring the efficacy of treatment in prostate cancers.

show abstract

Prostate Cancer Screening

Cited by 24 publications

References 55 publications

Global Methylation Profiling for Risk Prediction of Prostate Cancer

Global Methylation Profiling for Risk Prediction of Prostate Cancer

Is serum glutathione level in combination with serum PSA useful for early detection of prostatic carcinoma? A local study of Iraq

Comparison Between Circulating Immune Complexes and Prostate Specific Antigen to Assess the Pathogenesis of Prostate Cancer

Contact Info

Product

Resources

About